Company Overview
Product
Research & Development
Investor Relations
Company Overview
Product
Research & Development
Investor Relations
A wide range of news on Hana Pharm
- Signed a contract with AET(ALFRED E. TIFFENBACHER) on exclusive basis, plans to launch First-generic product in 2021
- Expects synergy effects on pain-related market through moderate to severe chronic/cancer pain patch product
Hana Pharm(293480, CEO Younha Lee) announced on the 25th that has signed a contract with AET(ALFRED E. TIEFENBACHER), global pharmaceutical company in Germany, of two products “Buprenorphine patch”, a moderate to severe chronic/cancer pain drug.
Buprenorphine patch is indicated for the management of moderate to severe chronic/cancer pain which does not respond to non-opioid analgesics. For chronic pain, use strength of 5, 10, and 20 μg/h every 7 days and 35, 52.5 and 70 μg/h every 4 days for cancer pain.
Patch formulation can be used comfortably for older patients not to have any gastrointestinal side effects. Furthermore, with or without experience on taking other similar drugs, it is possible to have sufficient curative effects and to use other drugs at the same time.
“ AET, part of TIEFENBACHER Group, a global family owned pharmaceutical company based in Germany, is a company that has established a global distribution network through in/out-licensing business. Through this agreement, Hana Pharm will introduce AET's high-quality drugs for the first time in Korea.” said Younha Lee, CEO of Hana Pharm. “We will make efforts to bring in more excellent drugs through AET, and AET's global distribution network will be an important bridgehead for Hana Pharm's future expansion into overseas markets.”
Hana Pharm aims to launch Buprenorphine patch and Fentanyl buccal tablet in 2021 as a First-generic product in South Korea. By bring two analgesics, used for acute and chronic pain, Hana Pharm is expected to continue leading the pain market.